1s78: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
We have determined the 3.2 A X-ray crystal structure of the extracellular, domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in, a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2, monoclonal antibody also known as 2C4 or Omnitarg. Pertuzumab binds to, ErbB2 near the center of domain II, sterically blocking a binding pocket, necessary for receptor dimerization and signaling. The ErbB2-pertuzumab, structure, combined with earlier mutagenesis data, defines the pertuzumab, residues essential for ErbB2 interaction. To analyze the ErbB2 side of the, interface, we have mutated a number of residues contacting pertuzumab and, examined the effects of these mutations on pertuzumab binding and, ErbB2-ErbB3 heterodimerization. We have also shown that conserved residues, previously shown to be necessary for EGF receptor homodimerization may be, dispensible for ErbB2-ErbB3 heterodimerization.
We have determined the 3.2 A X-ray crystal structure of the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2 or HER2) in a complex with the antigen binding fragment of pertuzumab, an anti-ErbB2 monoclonal antibody also known as 2C4 or Omnitarg. Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling. The ErbB2-pertuzumab structure, combined with earlier mutagenesis data, defines the pertuzumab residues essential for ErbB2 interaction. To analyze the ErbB2 side of the interface, we have mutated a number of residues contacting pertuzumab and examined the effects of these mutations on pertuzumab binding and ErbB2-ErbB3 heterodimerization. We have also shown that conserved residues previously shown to be necessary for EGF receptor homodimerization may be dispensible for ErbB2-ErbB3 heterodimerization.


==Disease==
==Disease==
Line 18: Line 18:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Transferase]]
[[Category: Transferase]]
[[Category: Carey, K.D.]]
[[Category: Carey, K D.]]
[[Category: Franklin, M.C.]]
[[Category: Franklin, M C.]]
[[Category: Leahy, D.J.]]
[[Category: Leahy, D J.]]
[[Category: Sliwkowski, M.X.]]
[[Category: Sliwkowski, M X.]]
[[Category: Vajdos, F.F.]]
[[Category: Vajdos, F F.]]
[[Category: Vos, A.M.de.]]
[[Category: Vos, A M.de.]]
[[Category: NAG]]
[[Category: NAG]]
[[Category: cysteine-rich domain]]
[[Category: cysteine-rich domain]]
Line 30: Line 30:
[[Category: receptor-antibody complex]]
[[Category: receptor-antibody complex]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:52:48 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:58:43 2008''